Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
NCT07503652
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Palmoplantar Pustulosis (PPP)
Interventions
DRUG:
Xeligekimab Injection
Sponsor
First Hospital of China Medical University